Translational evidence for portfolio decisions
The client made informed go/no-go decisions. The work supported regulatory success and found new ways to reposition and differentiate products.
A clear, independent view of what an asset is worth and who it is for.
Before you license, acquire or invest, you need to know whether the science will hold up in patients.
We assess an asset along its whole path, from preclinical data to clinical results and real-world use. We look at how the drug works, what the trials show, and how it would fit in practice.
You get:
Where it helps, we use biomarkers and patient stratification to support precision medicine.
The client made informed go/no-go decisions. The work supported regulatory success and found new ways to reposition and differentiate products.
Initial discussions are confidential and without obligation. Send a short note and we will reply.